Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(8%)
Results Posted
0%(0 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
1
8%
Ph not_applicable
5
42%
Ph phase_3
2
17%
Ph phase_4
4
33%

Phase Distribution

0

Early Stage

1

Mid Stage

6

Late Stage

Phase Distribution12 total trials
Phase 2Efficacy & side effects
1(8.3%)
Phase 3Large-scale testing
2(16.7%)
Phase 4Post-market surveillance
4(33.3%)
N/ANon-phased studies
5(41.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

1

trials recruiting

Total Trials

12

all time

Status Distribution
Active(1)
Completed(7)
Terminated(1)
Other(3)

Detailed Status

Completed7
unknown3
Terminated1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (8.3%)
Phase 32 (16.7%)
Phase 44 (33.3%)
N/A5 (41.7%)

Trials by Status

unknown325%
completed758%
terminated18%
recruiting18%

Recent Activity

1 active trials
Showing 5 of 12
recruitingphase_2

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

NCT05133804
completedphase_4

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

NCT00853866
completednot_applicable

Studying the Role of Brain Molecules for Decision Making

NCT04384562
completednot_applicable

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

NCT03957174
completednot_applicable

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

NCT04371146
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT05133804Phase 2

Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD

Recruiting
NCT00853866Phase 4

Enhancement of Motor Function with Reboxetine and Transcranial Direct Current Stimulation

Completed
NCT04384562Not Applicable

Studying the Role of Brain Molecules for Decision Making

Completed
NCT03957174Not Applicable

Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans

Completed
NCT04371146Not Applicable

The Role of Dopaminergic and Noradrenergic Neurotransmission in Value- and Salience-based Decision-Making

Completed
NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated
NCT02179268Phase 3

Antidepressants and Bone Mineral Density

Completed
NCT00421369Not Applicable

Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

Completed
NCT01300364Phase 4

Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

Unknown
NCT00209807Phase 4

Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder

Unknown
NCT00993876Not Applicable

Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment

Completed
NCT00426946Phase 4

Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12